Immunomodulatory approaches such as GRI-0621 (RARβγ agonist targeting iNKT activity) may support alveolar basement membrane repair and provide complementary biology for oral combination regimens.

United Therapeutics (NasdaqGS:UTHR) reported full Phase 3 TETON-2 trial data for nebulized Tyvaso in idiopathic pulmonary ...

Orphan status in the U.S. can confer clinical-trial tax credits, user-fee exemptions, and up to seven years of post-approval market exclusivity for rare-disease programs. As a deuterated form of ...

GRI Bio’s lead candidate, tazarotene, has exhibited disease-modifying potential in a mid-stage study in idiopathic pulmonary fibrosis (IPF). In the US-based Phase IIa study (NCT06331624), tazarotene ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Prior to this trial, CS014 had positive outcomes in an ...

IPF is a rare, progressive and fatal lung disease with a median survival of 2-5 years. 1 Pirfenidone is one of only two drugs approved to treat IPF, and for those patients able to tolerate treatment, ...

Following the End-of-Phase 2 meeting with the FDA, the Company gained alignment on its Phase 3 program for the treatment of patients with ...

BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with ...

Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks! Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks An announcement from PureTech Health ...

Idiopathic pulmonary fibrosis (IPF) is a rapidly progressive, fatal disease of unknown cause. Although there is no known cure, there have been indications that gastroesophageal reflux disease (GERD) ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Gersten: I've ...

NASHVILLE, Tenn. and CAMBRIDGE, England, May 13, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company with development efforts focused on new ...